These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27883282)

  • 21. Understanding EMPA-REG OUTCOME.
    Ceriello A; Genovese S; Mannucci E; Gronda E
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):929-30. PubMed ID: 26590680
    [No Abstract]   [Full Text] [Related]  

  • 22. Understanding EMPA-REG OUTCOME.
    Gilbert RE; Connelly KA
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):930-1. PubMed ID: 26590681
    [No Abstract]   [Full Text] [Related]  

  • 23. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Rosenstein R; Hough A
    N Engl J Med; 2016 Mar; 374(11):1093-4. PubMed ID: 26981944
    [No Abstract]   [Full Text] [Related]  

  • 24. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Fischereder M; Schönermarck U
    N Engl J Med; 2016 Mar; 374(11):1092-3. PubMed ID: 26981942
    [No Abstract]   [Full Text] [Related]  

  • 25. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Sarafidis PA; Tsapas A
    N Engl J Med; 2016 Mar; 374(11):1092. PubMed ID: 26981941
    [No Abstract]   [Full Text] [Related]  

  • 26. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B; Lachin JM; Inzucchi SE
    N Engl J Med; 2016 Mar; 374(11):1094. PubMed ID: 26981940
    [No Abstract]   [Full Text] [Related]  

  • 27. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Edwards JL
    N Engl J Med; 2016 Mar; 374(11):1093. PubMed ID: 26981943
    [No Abstract]   [Full Text] [Related]  

  • 28. Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
    Arbel R; Hammerman A; Azuri J
    Am J Cardiol; 2018 Sep; 122(6):981-984. PubMed ID: 30075890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors and the cardiovascular system].
    Fiorentino TV; Sesti G
    G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):13S-19. PubMed ID: 28151517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives.
    Jørgensen NB; Pedersen J; Vaag AA
    J Diabetes Complications; 2016; 30(4):753. PubMed ID: 26970674
    [No Abstract]   [Full Text] [Related]  

  • 31. Preventing cardiovascular events with empagliflozin: at what cost?
    Naci H; Basu S; Yudkin JS
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):931. PubMed ID: 26590682
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes.
    Ingelfinger JR; Rosen CJ
    N Engl J Med; 2015 Nov; 373(22):2178-9. PubMed ID: 26605932
    [No Abstract]   [Full Text] [Related]  

  • 33. Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
    Chudleigh RA; Bain S
    Expert Opin Drug Saf; 2017 May; 16(5):627-635. PubMed ID: 28387138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liraglutide and cardiovascular outcomes in type 2 diabetes.
    Jones B
    Ann Clin Biochem; 2016 Nov; 53(6):712. PubMed ID: 28071177
    [No Abstract]   [Full Text] [Related]  

  • 35. [SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].
    MMW Fortschr Med; 2015 Oct; 157(18):86-7. PubMed ID: 26985517
    [No Abstract]   [Full Text] [Related]  

  • 36. [Comment by Prof. Dr. med Dirk Müller-Wieland. The therapeutic goal for blood sugar lowering in diabetes treatment].
    Müller-Wieland D
    Med Monatsschr Pharm; 2016 Feb; 39(2):63. PubMed ID: 26983334
    [No Abstract]   [Full Text] [Related]  

  • 37. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke.
    Gerstein H; Jaeschke R
    Pol Arch Med Wewn; 2016 Oct; 126(10):803-805. PubMed ID: 27872459
    [No Abstract]   [Full Text] [Related]  

  • 38. ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years.
    Shekelle P
    Ann Intern Med; 2016 Jan; 164(2):JC2. PubMed ID: 26784492
    [No Abstract]   [Full Text] [Related]  

  • 39. Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus.
    Zimmermann J
    Am Fam Physician; 2016 Dec; 94(12):1014-1015. PubMed ID: 28075091
    [No Abstract]   [Full Text] [Related]  

  • 40. Superiority trials: statistical trickery or mass blindness?
    Shafiq N; Malhotra S
    Postgrad Med J; 2016 Feb; 92(1084):118-9. PubMed ID: 26621824
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.